Objective: The purpose of this study was to evaluate changes in health care resource utilization following the initiation of perampanel for the treatment of epilepsy in the United States. respectively. Additionally, a significantly lower rate of status epilepticus in the postperiod (1.8 events per 100 person-years) was observed compared to the pre-period (4.4 events per 100 person-years; RR = 0.43, p < 0.001). The monthly time trend of hospitalizations showed an increasing trend leading up to the initiation of perampanel, after which the hospitalizations decreased steadily. Significance: Use of perampanel for the treatment of epilepsy was associated with significant reduction in all-cause and epilepsy-related health care resource utilization, including hospitalizations, especially for status epilepticus, and outpatient visits.
Epilepsy is one of the most common debilitating neurological disorders in the United States. 1 According to the Center for Disease Control and Prevention, approximately 2.9 million people had active epilepsy in the United States in 2013. 2 Epilepsy is characterized by partial-onset (focal) seizures (POS) or generalized seizures, with POS being the most common type. 3 The economic and societal burden associated with epilepsy is substantial. It is estimated that epilepsy accounts for approximately $15.5 billion in direct and indirect costs annually. 2 The primary goal of treatment in epilepsy is the control of seizures, and use of antiepileptic drugs (AEDs) is the mainstay of therapy. 4 Despite the availability of numerous AEDs with various mechanisms of action, including sodium channel blockers, calcium current inhibitors, and c-aminobutyric acid enhancers, approximately 30% of patients still have uncontrolled seizures. 5 Failure to control seizures has been demonstrated to be associated with higher health care resource utilization and costs, underscoring the need for more effective AEDs. 6 Perampanel is the first orally active drug in a novel class of noncompetitive a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid-type glutamate receptor antagonists. 7 It was approved by the U.S. Food and Drug Administration in 2012 as an adjunctive treatment for POS, with or without secondarily generalized seizures in patients aged 12 years or older. In 2015, it was approved as an adjunctive treatment for primary generalized tonicclonic seizures (GTCS). 7 The efficacy of perampanel was demonstrated in four phase III, multicenter, randomized, double-blind, placebo-controlled trials (Trials 304, 305, and 306 in patients with POS, and Trial 332 in patients with GTCS) that evaluated perampanel in patients aged 12 years or older without adequate seizure control despite treatment with up to three AEDs. [8] [9] [10] [11] [12] The trials demonstrated significant reduction in seizure frequency with perampanel compared to placebo among patients with POS (median percentage reduction from baseline   per 28 days, Trial 304: 21%, 26%, and 35% for placebo  and perampanel 8 and 12 mg, respectively; Trial 305:  10%, 31%, and 18% for placebo and perampanel 8 and  12 mg, respectively; and Trial 306: 11%, 23%, and 31% for placebo and perampanel 4 and 8 mg, respectively; p < 0.05 for each trial-specific perampanel dose vs. placebo comparison) [9] [10] [11] and GTCS (median percentage reduction from baseline per 28 days: 38% and 76% for placebo and perampanel 8 mg, respectively; p < 0.05). 12 Similar improvements in clinical outcomes have been observed with perampanel in studies conducted in nonclinical trial settings. 13 Although the efficacy of perampanel has been demonstrated in clinical trial settings, it is unknown how the clinical benefits are translated into real-world outcomes. Hence, the current study aims to investigate whether perampanel use is associated with reduction in health care resource utilization, using a large nationally representative claims database that captures approximately 75% of the U.S. population cross-sectionally.
Methods

Study design and population
A self-controlled, pre-post design was chosen to alleviate confounding issues that are likely to arise with treatment choice bias in real-world practices. In a nonexperimental, nonrandomized, observational setting, physicians may prescribe different AEDs to different patients based on their clinical activity differences, making it difficult to compare patients receiving perampanel versus another AED, due to their observed and unobserved differences. Instead, we assembled a cohort of perampanel patients, using themselves as their own controls, by comparing time periods before versus after perampanel initiation. This retrospective, longitudinal, prepost study compared health care resource utilization before and after the initiation of perampanel among patients with a diagnosis of epilepsy. The date of the first perampanel dispensing is defined as the "index date." Patients were included in the study if they were newly initiated on perampanel between December 2012 and November 2015, had continuous clinical activity (i.e., at least one drug claim in each consecutive quarter) for at least a 6-month period before the index date (i.e., preperampanel period) and at least 6 months after the index date, and had at least one epilepsy diagnosis • All-cause and epilepsy-related hospitalizations and outpatient visits were significantly reduced after perampanel initiation
• Status epilepticus hospitalization rates were also significantly reduced, by >50%, after perampanel initiation than 12 years at the index date were excluded from the study.
Data source
Symphony Health's Patient Integrated Dataverse database, a large nationally representative provider-based claims database, over the period from December 2012 to November 2015, was used for the study. The database cross-sectionally covers about three-fourths of the U.S. population (or about 260 million lives) annually. It includes claims submitted to all payer types, including commercial plans, Medicare Part D, cash, assistance programs, and Medicaid.
14 In terms of the pharmacy claims, it captures approximately 70% of the retail and specialty pharmacy claims and approximately 55% of mail orders. For medical claims, it covers approximately 55% of professional claims and 30% of institutional claims in the country. The data are deidentified, in compliance with the Health Insurance Portability and Accountability Act.
Study outcomes
The study endpoints were health care resource utilization outcomes, including all-cause and epilepsy-related hospitalizations and outpatient visits. Hospitalizations and outpatient visits were identified in the data through a variable indicating place of service. Consecutive days of hospital inpatient visits were considered as the same hospitalization episode. Epilepsy-related health care resource utilization was identified as any hospitalization or outpatient visit with a primary or secondary diagnosis of epilepsy (ICD-9-CM 345.xx or ICD-10-CM G40.xxx). Hospitalizations associated with status epilepticus were identified as any hospitalization with a primary or secondary diagnosis of status epilepticus (ICD-9-CM code 345.3x and ICD-10-CM code G40.30). Health care resource utilization was evaluated during the 6 months before the index date (i.e., preperampanel period) and during the observation period after the index date (i.e., postperampanel period).
Statistical analyses
Patient baseline demographic and clinical characteristics were described using mean and standard deviation (SD) for continuous variables, and frequency and proportions for categorical variables. The baseline characteristics included age, gender, geographic region, insurance plan type, year of index date, clinical epilepsy-related characteristics such as type of epileptic seizures and prior epilepsy-related events (i.e., head trauma, fractures, motor vehicle accidents), and prior AED medications (monotherapy, polytherapy, and concomitant AED). Comorbidities during the baseline period included Quan-Charlson Comorbidity Index (CCI), central nervous system-specific comorbidities (i.e., Alzheimer's disease, bipolar disorder, brain tumor, cerebrovascular disease, depression, meningitis, mental retardation, other mood disorders, and tuberous sclerosis), and other common comorbidities (i.e., anemia, pulmonary disease, cardiovascular diseases, diabetes, gastrointestinal diseases, and stroke).
All-cause and epilepsy-related health care resource utilization outcomes were measured during the pre-and postperampanel periods and presented as event rates (frequency of each health care resource utilization outcome/100 person-years of follow-up). The mean number of all-cause and epilepsy-related hospitalizations per active patient (i.e., patients with >15 days of observation during a given month) in the pre-and postperampanel periods was also calculated. The impact of initiation of perampanel on each health care resource utilization outcome was evaluated by comparing event rates in the pre-and postperampanel periods using conditional Poisson regression models, adjusting for correlations between the pre-and post-periods within the same patient. 15 Results are presented as rate ratios (RRs) with corresponding 95% confidence intervals (CIs).
All significance tests were two-sided, and differences were considered significant at p < 0.05. All analyses were conducted using SAS 9.4 (SAS Institute, Cary, NC, U.S.A.).
Results
Figure 1 displays the population disposition flow chart; a total of 2,508 patients fulfilled the eligibility criteria for the study. Table 1 Epilepsy-related hospitalizations and outpatient visits were also significantly reduced after perampanel initiation (Table 2) Table 2 ). Figure 2 depicts the time trend of the mean number of allcause and epilepsy-related hospitalizations per patient by month from the pre-to postperampanel periods. Mean number of all-cause and epilepsy-related hospitalizations per patient sharply increased in the pre-period and peaked at the month immediately before perampanel initiation. The mean hospitalization rates then dropped precipitously after perampanel initiation, followed by a sustained decrease over time.
Discussion
This retrospective study based on real-world claims data of a cohort of >2,500 patients receiving perampanel for the treatment of epilepsy showed significant benefits of perampanel on health care resource utilization outcomes. All-cause and epilepsy-related hospitalizations and outpatient visits were significantly reduced after perampanel initiation. Patients had significantly fewer status epilepticus hospitalizations in the postperampanel compared to the preperampanel period.
This study is the first to examine the benefits of perampanel on health care resource utilization in patients with epilepsy. The study has several strengths. It is based on a large transactional claims database that captures >50% of the prescription claims in United States, resulting in the largest perampanel study cohort in a real-world setting. Because the database captures a large proportion of prescription claims in the United States, the results may be generalizable to the U.S. epilepsy patient population.
To date, several clinical trials and observational studies have examined the impact of perampanel on clinical Monthly mean number of hospitalizations per patient before versus after perampanel initiation. A patient was counted in the denominator of a given month if he/ she had >15 days of observation during that month. Epilepsia ILAE outcomes (i.e., seizure control). [8] [9] [10] [11] [12] [16] [17] [18] The pooled analysis of three phase III clinical trials that evaluated perampanel in 1,480 patients with treatment-refractory epilepsy showed that perampanel use was associated with significantly improved responder rates (i.e., ≥50% reduction in all seizure frequency per 28 days) when compared to placebo (p < 0.01). 8 The median change in seizure frequency was significantly greater with perampanel compared to placebo (p < 0.01). Recent observational studies have also evaluated the impact of perampanel on seizure control in nonclinical trial settings. 17, 19 A recent study by Rohracher et al. 17 examined medical charts of 122 patients 12 years or older with POS who were treated with perampanel and found that 27% of patients receiving perampanel were seizure-free for 3 months at last follow-up and 15% were responders, with a reduction in seizure frequency ≥50% from baseline. Similar beneficial impact was observed by Steinhoff et al., 19 who studied 281 patients with POS across nine clinical centers. The study reported that 15% of patients were seizure-free in the preceding 3 months at last visit and 50% had at least 50% reduction in seizure frequency compared to the baseline period. The present study translates the clinical trial findings of improvement in clinical outcomes after perampanel treatment into less health service consumption in terms of fewer hospitalizations and outpatient visits in realworld clinical practice settings.
Several studies have demonstrated clinical efficacy of other AEDs used as an adjunctive therapy; however, studies examining the impact on economic outcomes are limited. [20] [21] [22] [23] A retrospective claims database study by Wang et al. 23 analyzed data for 1,353 patients with POS and compared economic outcomes among patients who changed from monotherapy to adjunctive therapy. The results showed significant decreases in average monthly percentage of patients with all-cause and epilepsy-related hospitalizations and emergency room visits in the adjunctive therapy compared to the monotherapy phase (p < 0.01). These findings of improved economic outcomes with adjunctive therapy among patients with epilepsy support the findings of the current study.
Studies examining the efficacy of perampanel among patients with status epilepticus are limited. [24] [25] [26] Status epilepticus is a prolonged, self-sustaining type of seizure and one of the most common neurological emergencies after stroke, with an estimated incidence between 10 and 41 cases per 100,000 patients in the United States. 13, 27, 28 The economic burden of this condition on the health care system is reported to be substantial, and cost of inpatient management is estimated to be higher than that for newly diagnosed or established epilepsy. 26, 29 The current study showed particularly significant reduction in hospitalizations associated with status epilepticus after perampanel initiation in the largest cohort of perampanel patients ever reported in the literature. This presumably reflects an ability of perampanel to prevent status epilepticus in persons with epilepsy. It is not known whether perampanel is effective for treating status epilepticus; only small uncontrolled reports are available. 24, 25 This study has several limitations. First, the Symphony Health database is an administrative claim database and may contain errors or omissions in codes for procedures, diagnoses, or dispensation. Second, this database is a provider-based data source, which may result in a patient being counted as multiple patients if seen by different doctors or hospitals that are not within the same network. Although the Symphony Health database utilizes an algorithm to link patients across different health care facilities and pharmacies based on patient identifiable information, the extent of nonmatch or mismatch is unknown. This potential for misclassification error may result in an underestimation of perampanel use at the patient level or linking the medical services to the wrong pharmacy dispensation records. Also, because the data source is provider-based, not insurancebased, the data source lacks patient eligibility files. Because clinical activity is used to indicate eligibility, healthier patients who have not incurred any clinical services would not have been included in the study. Finally, this study does not address the question of how addition of perampanel compares to addition of other antiepileptic drugs or initiation of other therapies in reduction of health care utilization. There is some evidence that "active management"-that is, making some change in therapy-reduces subsequent hospitalizations and emergency visits for epilepsy in comparison with no change at all in therapy. 30 One could also argue that epilepsy is a variable disease, that new drugs are likely to be initiated when it is more severe, and that a regression toward a mean of less severity may occur. However, the consistent and dramatic improvement after perampanel suggests a therapeutic effect, not a random variation.
Conclusion
This large cohort of patients with epilepsy receiving perampanel showed that treatment of perampanel was associated with a significant decrease in all-cause and epilepsyrelated hospitalizations and outpatient visits. In particular, perampanel was associated with reducing the status epilepticus hospitalization rates by >50%.
